HeartRhythm

AUGUST 31, 2024

Patients with CLL are at increased risk of developing atrial fibrillation (AF), however AF is a known side effect of ibrutinib therapy as well and is associated with worse outcomes. The role of wearable technology in detecting AF in cardio-oncology has not been well defined.

Cardio Oncology 40

Cardio Oncology Technology Atrial Fibrillation Arrhythmia 40

DAIC

FEBRUARY 28, 2024

The emerging field of cardio-oncology is paving the way for expert, multidisciplinary heart care before, during and after cancer treatment to mitigate adverse effects on cardiovascular health.

Risk Factors 105

Risk Factors Cancer Cardio Oncology Blood Pressure 105

Heart BMJ

NOVEMBER 27, 2023

There is need for development of a stronger evidence base to guide clinical practice in cardio-oncology. The establishment of multicentre international registries and national-level healthcare data linkage projects are important steps towards facilitating enrichment of cardio-oncology research programmes.

Cardio Oncology 40

Cardio Oncology Cancer Cardiovascular Disease Risk Factors 40

DAIC

JUNE 12, 2024

The new FDA-cleared AI-enabled applications include the industry’s first automated tool for segmental wall motion scoring of the heart to quickly and objectively identify disorders including coronary artery disease and cardio-oncology issues in seconds.

Ultrasound 105

Ultrasound Cardio Oncology Congenital Heart Disease Technology 105

DAIC

APRIL 3, 2024

Improve global care outcomes through the distribution of educational materials to clinicians in underserved communities worldwide and through support of quality improvement programs that save lives. Advance health equity through education, advocacy and science. 24 news here.

Education 105

Education Preserved Ejection Fraction Coronary Artery Disease Cardio Oncology 105

Cardiology Update

JANUARY 2, 2024

’ This focus is dedicated to empowering patients by providing customized treatments to enhance outcomes, minimize risks, and redefine the benchmark for standard care.

Heart Failure 111

Heart Failure Atherosclerosis Cardiovascular Imaging Non-Invasive Cardiology 111

Cardiology Update

APRIL 9, 2024

The percent change from baseline in fasting triglycerides (TG) at six months served as the primary outcome measure. The percent change from baseline in fasting TG at six months served as the primary outcome measure. Among patients with HFpEF, those who received the shunt experienced poor outcomes than those who did not.

Angina 52

Angina Myocardial Infarction Aortic valve Coronary Artery Disease 52